Filing Analysis
Contineum Therapeutics, Inc. filed an 8-K to furnish its financial results for the second quarter ended June 30, 2026. The filing serves as a placeholder for the press release containing the quarterly earnings data.
📋 Key Facts
- Company reported financial results for Q2 ended June 30, 2026.
- The report was filed on July 30, 2026.
- Financial results are provided via a press release furnished as Exhibit 99.1.
Contineum Therapeutics, Inc. has updated its corporate presentation to reflect recent business and strategic updates. This filing is a routine disclosure under Item 7.01 (Regulation FD Disclosure) intended to provide summary information via the company's website.
📋 Key Facts
- Company updated its corporate presentation on July 13, 2026.
- The update reflects certain business and strategic updates for the company.
- The updated presentation is attached as Exhibit 99.1.
- The company intends to use its website to disseminate future presentation updates without filing individual 8-Ks.
Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. The meeting resulted in the election of three Class II directors and the ratification of Ernst & Young LLP as the independent auditor for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held virtually on June 26, 2026.
- Elected Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D. as Class II directors to serve until the 2029 Annual Meeting.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
- Total shares outstanding/entitled to vote as of April 27, 2026: 32,723,877 Class A common stock.
Contineum Therapeutics, Inc. completed an upsized public offering of 7,346,938 shares of Class A common stock at $12.25 per share. The offering was significantly larger than initially proposed, increasing from a planned $75 million to approximately $90 million in gross proceeds.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 7.3 million new shares.
📋 Key Facts
- Offered 7,346,938 shares of Class A common stock at $12.25 per share.
- Underwriters (Goldman Sachs & Co. LLC and Leerink Partners LLC) purchased shares at $11.515 per share.
- Net proceeds to the company are estimated at approximately $84.2 million after discounts and expenses.
- The offering was upsized from an initial proposed amount of $75.0 million to a final pricing of $90.0 million.
- Underwriters have a 30-day option to purchase up to an additional 1,102,040 shares.
- Offering closed on December 15, 2025.
Contineum Therapeutics announced the submission of its global Phase 2 clinical trial protocol for PIPE-791 to ClinicalTrials.gov. The study aims to evaluate the safety and efficacy of once-daily dosing in patients with idiopathic pulmonary fibrosis (IPF).
🚩 Red Flags
- Long timeline to trial completion (June 2028) implies significant capital burn required over the next ~2.5 years.
- Standard forward-looking statement risk regarding cash sufficiency to fund operations.
📋 Key Facts
- Trial target: Global Phase 2 clinical trial of PIPE-791 for idiopathic pulmonary fibrosis (IPF).
- Study design: 26-week, international, randomized, dose-ranging, double-blind, placebo-controlled.
- Primary endpoint: Change from baseline in absolute forced vital capacity (FVC) at week 26.
- Subject enrollment: Approximately 324 subjects globally.
- Estimated completion date: June 2028.
Contineum Therapeutics, Inc. announced topline data from its Phase 2 PIPE-307 VISTA clinical trial for the treatment of relapsing-remitting multiple sclerosis.
📋 Key Facts
- Reported topline data from the Phase 2 PIPE-307 VISTA trial on November 20, 2025.
- The trial targets the treatment of relapsing-remitting multiple sclerosis (RRMS).
- Filing includes a press release as Exhibit 99.1.
Contineum Therapeutics, Inc. has filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2025.
📋 Key Facts
- The filing is a routine announcement of Q3 2025 financial results.
- Report date: October 30, 2025.
- Financial results were released via press release (Exhibit 99.1).
- Company is an emerging growth company.
Contineum Therapeutics reported positive topline data from its Phase 1b Positron Emission Tomography (PET) trial of PIPE-791. The study confirmed a pharmacokinetic relationship between drug exposure and LPA1 brain receptor occupancy in healthy volunteers and PrMS patients.
🚩 Red Flags
- Clinical trial data is preliminary (topline) and subject to future validation in larger trials.
📋 Key Facts
- Phase 1b PET trial was open-label, single-center, involving 12 healthy volunteers and 4 progressive multiple sclerosis (PrMS) patients.
- Confirmed PK relationship between PIPE-791 exposure and LPA1 brain receptor occupancy (RO).
- Plasma EC50 values were 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose, indicating sustained target engagement.
- Company anticipates planned Phase 2 doses will exceed 90% target coverage at trough with once-daily dosing.
Contineum Therapeutics, Inc. has filed an 8-K to furnish its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release issued on August 5, 2025.
📋 Key Facts
- The company reported financial results for the second quarter ended June 30, 2025.
- The report was filed on August 5, 2025.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Contineum Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 26, 2025. The meeting resulted in the election of three Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held virtually on June 26, 2025.
- Three Class I directors elected: Sarah Boyce, Troy Ignelzi, and Olivia Ware, to serve until the 2028 Annual Meeting.
- Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- As of April 28, 2025 record date, there were 19,142,377 shares of Class A common stock outstanding.
Contineum Therapeutics announced its Q1 2025 financial results and simultaneously filed a large-scale S-3 shelf registration for up to $300 million. Additionally, the company entered into an 'at-the-market' (ATM) sales agreement with Leerink Partners for up to $75 million in Class A common stock.
🚩 Red Flags
- Significant potential dilution: The $75M ATM agreement and the $300M shelf registration indicate a high likelihood of upcoming equity issuance to fund operations.
- Typical biotech cash burn profile implied by the scale of the offerings.
📋 Key Facts
- Filed a Form S-3 Shelf Registration Statement registering up to $300.0 million in securities over three years.
- Entered into a Sales Agreement with Leerink Partners LLC for an ATM offering of up to $75.0 million in Class A common stock.
- Announced Q1 2025 financial results (ended March 31, 2025) via press release.
- The company is classified as an emerging growth company.
Contineum Therapeutics, Inc. has appointed Timothy Watkins, M.D., M.Sc. as its new Chief Medical Officer and Head of Development, effective April 28, 2025.
📋 Key Facts
- Appointment of Timothy Watkins, M.D., M.Sc. as Chief Medical Officer (CMO) and Head of Development.
- Effective date of appointment: April 28, 2025.
- The announcement was made via an Item 8.01 Other Events filing.
Contineum Therapeutics, Inc. appointed Dr. Diego Miralles to its Board of Directors as a Class II director, effective March 14, 2025. This appointment involved the termination of his previous advisory agreement with the company.
🚩 Red Flags
- Director is deemed non-independent due to prior consulting/advisor relationship (potential related-party complexity).
📋 Key Facts
- Dr. Diego Miralles appointed to the Board on March 14, 2025.
- Dr. Miralles will serve as a Class II director; term expires at the 2026 annual meeting or until successor is elected.
- The Board determined Dr. Miralles is not independent due to prior compensation under an advisor agreement.
- A previous Advisor Agreement (started June 2024) providing $10,000/month and stock options was terminated effective March 14, 2025.
- New compensation includes an option to purchase 29,500 shares of Class A common stock under the Non-Employee Director Compensation Program.
Contineum Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the fourth quarter ended December 31, 2024.
📋 Key Facts
- Reporting period: Fourth quarter ended December 31, 2024.
- Filing date: March 6, 2025.
- The filing is under Item 2.02 (Results of Operations and Financial Condition).
- The report includes a press release as Exhibit 99.1.
Contineum Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended September 30, 2024, and provided a general corporate update via press release.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ending September 30, 2024.
- The company issued a corporate update alongside the earnings release.
- Report date: November 6, 2024.
This is an 8-K/A (Amendment No. 1) filed to correct a broken hyperlink in the original August 13, 2024 filing. The amendment serves to ensure investors can access Exhibit 99.1 containing Q2 2024 financial results and corporate updates.
🚩 Red Flags
- None identified in this specific amendment; it is a technical correction.
📋 Key Facts
- Filed on August 14, 2024, as an amendment to the original 8-K filed on August 13, 2024.
- Purpose of filing is solely to correct a hyperlink to Exhibit 99.1 in Item 9.01 of the original report.
- The original filing contained Q2 2024 financial results and a corporate update (Item 2.02).
- Company updated its corporate presentation on its website (Item 7.01).
Contineum Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided a corporate update via press release. The company also updated its corporate presentation on its website.
📋 Key Facts
- Reported financial results for the quarter ended June 30, 2024.
- Issued a corporate update alongside the earnings release.
- Updated the corporate presentation available on the company's website.
- The filing is an emerging growth company disclosure.
Contineum Therapeutics, Inc. announced the appointment of Sarah Boyce to its Board of Directors and her designation as Chair of the Nominating and Corporate Governance Committee, effective June 24, 2024.
📋 Key Facts
- Sarah Boyce appointed as a Class I director, effective June 24, 2024.
- Ms. Boyce will serve as Chair of the Nominating and Corporate Governance Committee, replacing Lori Lyons-Williams.
- Compensation includes an initial grant of an option to purchase 29,500 shares of Class A common stock under the existing Non-Employee Director Compensation Program.
- Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc. (RNA) and previously held leadership roles at Akcea Therapeutics, Ionis Pharmaceuticals, and Novartis.
Contineum Therapeutics has adopted an Executive Severance Plan to provide benefits to named executive officers and key employees. The plan includes tiered severance packages triggered by involuntary termination or changes in control.
🚩 Red Flags
- Establishment of severance plans can sometimes precede restructuring or leadership changes, though not explicitly stated here.
📋 Key Facts
- Board adopted the Executive Severance Plan on May 24, 2024.
- CEO Carmine Stengone is designated as a Tier 1 Participant (highest tier).
- CSO Daniel Lorrain and CFO Peter Slover are designated as Tier 2 Participants.
- Tier 1/2 participants receive 12 months of base salary + pro-rated bonus for non-change-in-control terminations.
- Change in control benefits for Tier 1 include 150% of annual base salary and target bonus, plus full vesting of equity awards.
Contineum Therapeutics, Inc. announced the appointment of Troy Ignelzi to its Board of Directors and as Chair of the Audit Committee, effective May 20, 2024. This appointment results in Evert Schimmelpennink stepping down from the Audit Committee.
📋 Key Facts
- Troy Ignelzi appointed to the Board of Directors as a Class I director, term expiring at the 2025 annual meeting.
- Mr. Ignelzi appointed as Chair of the Board’s Audit Committee; designated as an SEC audit committee financial expert.
- Evert Schimmelpennink stepped down from the Audit Committee following the appointment.
- Compensation includes an initial grant of 23,150 options to purchase Class A common stock under the existing Non-Employee Director Compensation Program.
- Mr. Ignelzi previously served as CFO at Karuna Therapeutics and Rapport Therapeutics.
Contineum Therapeutics, Inc. issued an 8-K to furnish its quarterly financial results for the period ended March 31, 2024, alongside a corporate update via press release.
📋 Key Facts
- Report date: May 16, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes financial results and a corporate update in Exhibit 99.1
- Company is an emerging growth company
Contineum Therapeutics, Inc. filed an 8-K to report the adoption of amended and restated articles of incorporation and bylaws in connection with its initial public offering (IPO). The changes include restructuring share classes and establishing governance protocols for a public company.
🚩 Red Flags
- Governance changes (eliminating written consent/special meetings) reduce shareholder control, which is common in IPOs but a structural red flag for minority investors.
📋 Key Facts
- The filing is in direct connection with the closing of the Company's IPO.
- Amended Certificate of Incorporation authorizes 220,000,000 shares (200M Class A; 20M Class B) and 10,000,000 undesignated preferred shares.
- Established a classified board of directors with three classes and staggered three-year terms.
- Implemented high voting thresholds for director removal (66.2/3% vote required).
- Restricted stockholder rights by eliminating the ability to take action by written consent or call special meetings.
- Designated Delaware Court of Chancery as the exclusive forum for derivative actions and federal district courts for Securities Act claims.